XML 43 R34.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-Based Compensation (Tables)
6 Months Ended
Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock Option Activity
A summary of the stock option activity under the Company’s equity plans and inducement awards, for the six months ended June 30, 2022 is as follows:
(number of shares in millions)Number
of
Shares
Weighted
Average
Exercise
Price
Options outstanding at December 31, 20211.4 $20.36 
Less:
Options exercised— $23.98 
Options canceled or expired(0.1)$25.26 
Options outstanding at June 30, 20221.3 $20.09 
Options exercisable at June 30, 20220.9 $22.91 
Schedule of Restricted Stock Unit Activity
A summary of the RSU awards activity under the Company’s equity plans and inducement awards, including RSU awards with performance metrics, for the six months ended June 30, 2022 is as follows:
(number of shares in millions)Number
of
Shares
Weighted
Average
Grant Date
Fair Value
RSUs outstanding at December 31, 20213.1 $24.96 
RSUs granted1.8 $26.50 
Less:
RSUs vested(0.6)$28.08 
RSUs canceled(0.2)$26.57 
RSUs outstanding at June 30, 20224.1 $25.07 
Schedule of Stock-Based Compensation Expense
Stock-based compensation expense recognized and included in the Condensed Consolidated Statements of Operations and Comprehensive Loss was allocated as follows:
Three months ended
June 30,
Six months ended
June 30,
(in millions)2022202120222021
Cost of molecular diagnostic testing$0.5 $0.4 $0.8 $0.7 
Cost of pharmaceutical and clinical services— — — 0.1 
Research and development expense1.0 1.0 3.4 2.5 
Selling, general, and administrative expense8.9 7.5 16.3 14.6 
     Total stock-based compensation expense$10.4 $8.9 $20.5 $17.9